Evidence map›Paper›PMID 37176018›Full record

ArticleInternational journal of molecular sciences2023

Rivastigmine-Benzimidazole Hybrids as Promising Multitarget Metal-Modulating Compounds for Potential Treatment of Neurodegenerative Diseases.

David Vicente-Zurdo, Leonardo Brunetti, Luca Piemontese, Beatriz Guedes, Sandra M Cardoso, Daniel Chavarria, Fernanda Borges, Yolanda Madrid, Sílvia Chaves, M Amélia Santos

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Recent Advances in the Search for Effective Anti-Alzheimer's Drugs.International journal of molecular sciences · 2024
    Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

David Vicente-ZurdoCentro de Química Estrutural, Departamento de Engenharia Química, Institute of Molecular Sciences, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais 1, 1049-001 Lisboa, Portugal.ORCID 0000-0001-8946-2858
Leonardo BrunettiCentro de Química Estrutural, Departamento de Engenharia Química, Institute of Molecular Sciences, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais 1, 1049-001 Lisboa, Portugal.ORCID 0000-0002-7787-6639
Luca PiemonteseDepartment of Pharmacy-Pharmaceutical Sciences, University of Bari Aldo Moro, via E. Orabona 4, 70125 Bari, Italy.ORCID 0000-0002-7980-5818
Beatriz GuedesCNC-Center for Neuroscience and Cell Biology, University of Coimbra, 3000-370 Coimbra, Portugal.ORCID 0000-0002-8171-9062
Sandra M CardosoCNC-Center for Neuroscience and Cell Biology, University of Coimbra, 3000-370 Coimbra, Portugal.ORCID 0000-0002-2199-0555
Daniel ChavarriaCIQUP-IMS, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Rua do Campo Alegre s/n, 4169-007 Porto, Portugal.ORCID 0000-0002-7010-9808
Fernanda BorgesCIQUP-IMS, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Rua do Campo Alegre s/n, 4169-007 Porto, Portugal.ORCID 0000-0003-1050-2402
Yolanda MadridDepartment of Analytical Chemistry, Faculty of Chemistry, Complutense University of Madrid, Avenida Complutense s/n, 28040 Madrid, Spain.
Sílvia ChavesCentro de Química Estrutural, Departamento de Engenharia Química, Institute of Molecular Sciences, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais 1, 1049-001 Lisboa, Portugal.ORCID 0000-0002-8554-4992
M Amélia SantosCentro de Química Estrutural, Departamento de Engenharia Química, Institute of Molecular Sciences, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais 1, 1049-001 Lisboa, Portugal.ORCID 0000-0002-4069-9368
University of Lisbon · PTUniversidad Complutense de Madrid · ESUniversidade do Porto · PTUniversity of Coimbra · PTUniversity of Bari Aldo Moro · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the goal of combating the multi-faceted Alzheimer's disease (AD), a series of Rivastigmine-Benzimidazole (RIV-BIM) hybrids was recently reported by us as multitarget-directed ligands, thanks to their capacity to tackle important hallmarks of AD. In particular, they exhibited antioxidant activity, acted as cholinesterase inhibitors, and inhibited amyloid-

Indexed as

Alzheimer DiseaseNeuroblastomaNeurodegenerative DiseasesAmyloid beta-PeptidesBenzimidazolesChelating AgentsCholinesterase InhibitorsFerric CompoundsHumansMonoamine OxidaseRivastigmineAmyloid beta-PeptidesBenzimidazolesChelating AgentsCholinesterase InhibitorsFerric CompoundsMonoamine OxidaseRivastigmineAlzheimer’s diseaseamyloid-β aggregationcholinesterasesmetal chelationmonoamine oxidaseParkinson’s diseaserivastigmine hybrids

Identifiers

PMID37176018
PMCPMC10179505
OpenAlexW4372291829

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.